Subscribe today to HTA Quarterly - the e-newsletter with insights to bridge science and policy.

As a strategic consulting partner for hundreds of brands, we’ve learned what insights HEOR and Market Access teams find most useful. And we’ve designed an e-newsletter specifically with your needs in mind.

Take a look at what's in our current issue: 

  • When the Outcome of an Appraisal Is Not NICE: An Overview of the Appeal Process
  • Navigating Coverage and Reimbursement for Immunotherapy in Oncology: Perspectives on Challenges and Opportunities in the HTA Evaluation Process
  • Revisiting the Familiar: Time to Re-evaluate the GVD?
  • Updated HTA Decision Map: How New Products Are Faring With Authorities in Europe, Canada, and More

From at-a-glance updates on important HTA decisions, to reviews that shine a spotlight on what those decisions mean for specific therapeutic areas, each edition of the HTA Quarterly provides insight into the evolving perspectives and priorities for HTAs; as well as Xcenda’s unique perspective so you are more prepared to address the challenges of an uncertain and rapidly changing healthcare environment.